June 2022
Volume 63, Issue 7
Open Access
ARVO Annual Meeting Abstract  |   June 2022
Findings on visual photosensitivity in two phase 1/2 clinical trials of subretinal gene therapy with AGTC-401 and AGTC-402 for CNGB3 and CNGA3 achromatopsia
Author Affiliations & Notes
  • Rachel M Huckfeldt
    Massachusetts Eye and Ear, Boston, Massachusetts, United States
  • Jason Comander
    Massachusetts Eye and Ear, Boston, Massachusetts, United States
  • Mark E Pennesi
    Oregon Health & Science University Casey Eye Institute, Portland, Oregon, United States
  • Paul Yang
    Oregon Health & Science University Casey Eye Institute, Portland, Oregon, United States
  • Andreas Lauer
    Oregon Health & Science University Casey Eye Institute, Portland, Oregon, United States
  • Robert Sisk
    Cincinnati Eye Institute, Cincinnati, Ohio, United States
  • Edward Averbukh
    Hadassah Medical Center, Jerusalem, Jerusalem, Israel
  • Eyal Banin
    Hadassah Medical Center, Jerusalem, Jerusalem, Israel
  • Ninel Z Gregori
    University of Miami Health System Bascom Palmer Eye Institute, Miami, Florida, United States
  • Janet L Davis
    University of Miami Health System Bascom Palmer Eye Institute, Miami, Florida, United States
  • Byron L Lam
    University of Miami Health System Bascom Palmer Eye Institute, Miami, Florida, United States
  • Christine Nichols Kay
    VitreoRetinal Associates PA, Gainesville, Florida, United States
  • Jessica Ijams Wolfing Morgan
    University of Pennsylvania, Philadelphia, Pennsylvania, United States
  • Joseph Carroll
    Medical College of Wisconsin, Milwaukee, Wisconsin, United States
  • Bright Senyo Ashimatey
    AGTC, Alachua, Florida, United States
  • Matthew Feinsod
    AGTC, Alachua, Florida, United States
  • Footnotes
    Commercial Relationships   Rachel Huckfeldt AGTC, Annexon Bioscience, Intergalactic Therapeutics, ProQR, Regeneron, Vida Ventures, Code C (Consultant/Contractor), AGTC, Biogen, Foundation Fighting Blindness, MeiraGTx, ProQR, Spark Therapeutics, Code F (Financial Support), Choroideremia Research Foundation, Code S (non-remunerative); Jason Comander AGTC, Code C (Consultant/Contractor), AGTC, Code F (Financial Support); Mark Pennesi AGTC, Code C (Consultant/Contractor), AGTC, Code F (Financial Support); Paul Yang AGTC, Code F (Financial Support); Andreas Lauer AGTC, Code C (Consultant/Contractor), AGTC, Code F (Financial Support); Robert Sisk AGTC, Code C (Consultant/Contractor), AGTC, Code F (Financial Support); Edward Averbukh AGTC, Code F (Financial Support); Eyal Banin AGTC, Code F (Financial Support); Ninel Gregori AGTC, Code F (Financial Support); Janet Davis AGTC, Code F (Financial Support); Byron Lam AGTC, Code F (Financial Support); Christine Kay AGTC, Code C (Consultant/Contractor), AGTC, Code F (Financial Support); Jessica Morgan AGTC, Code F (Financial Support); Joseph Carroll AGTC, Code C (Consultant/Contractor), AGTC, MeiraGTx, Code F (Financial Support), Translational Imaging Innovations, Code I (Personal Financial Interest); Bright Ashimatey AGTC, Code E (Employment); Matthew Feinsod AGTC, Code E (Employment)
  • Footnotes
    Support  Note: No grants. My institution receives funds on my behalf as part of the clinical trial agreement that supports the clinical trial described in the abstract.
Investigative Ophthalmology & Visual Science June 2022, Vol.63, 450. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Rachel M Huckfeldt, Jason Comander, Mark E Pennesi, Paul Yang, Andreas Lauer, Robert Sisk, Edward Averbukh, Eyal Banin, Ninel Z Gregori, Janet L Davis, Byron L Lam, Christine Nichols Kay, Jessica Ijams Wolfing Morgan, Joseph Carroll, Bright Senyo Ashimatey, Matthew Feinsod; Findings on visual photosensitivity in two phase 1/2 clinical trials of subretinal gene therapy with AGTC-401 and AGTC-402 for CNGB3 and CNGA3 achromatopsia. Invest. Ophthalmol. Vis. Sci. 2022;63(7):450.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Achromatopsia (ACHM) is an autosomal recessive retinal disorder associated with photosensitivity, absent color discrimination, and decreased visual acuity. We describe the effects of the subretinal gene therapies AGTC-401 and AGTC-402 on photosensitivity at Month(M) 12 and M24 post-treatment.

Methods : Participants with ACHM due to biallelic mutations in either CNGA3 (n=15; 2<18y) or CNGB3 (n=25; 4<18y) were sequentially assigned to one of 5 (CNGA3) or 6 (CNGB3) dose levels before receiving a single subretinal injection of AGTC-402 (rAAV2tYF-PR1.7-hCNGA3) or AGTC-401 (rAAV2tYF-PR1.7-hCNGB3) involving the macula of the study eye (SE). Safety and efficacy assessments included best-corrected visual acuity (BCVA; ETDRS letter score) and photosensitivity, which was measured as the light discomfort threshold (LDT). Two tests assessed LDT: LDT-1 using a full-field light stimulus generated by the Diagnosys ColorDome and LDT-2 using the Ocular Photosensitivity Analyzer. A meaningful post-treatment response in LDT was defined as an increase from baseline >1 loglux.

Results : In these participants with at least 12 months of follow-up, AGTC-401 and AGTC-402 were generally well-tolerated; serious adverse events were related to the surgical procedure (n=1) and steroid-associated elevated intraocular pressure (n=2). Mean BCVA changed by < 3 letters in both trials. Mean LDT at M12 was higher on LDT-1 in the CNGB3 trial (p=0.002) but unchanged on LDT-1 in the CNGA3 trial and on LDT-2 in both trials. The CNGB3 trial had 4 LDT-1 and 9 LDT-2 responders with the greatest number (LDT-1, n=3; LDT-2, n=6) in the pediatric and highest dose groups (1.1e12 and 3.2e12 vg/ml). All LDT-1 responders were also LDT-2 responders. Improved LDT was sustained in 3 of 4 LDT-2 responders with M24 data. Untreated fellow eyes showed >1 loglux change in 75% of LDT-1 and 67% of LDT-2 responders. The CNGA3 trial had 2 LDT-1 and 2 LDT-2 responders among 3 participants with sustained improvement at M24 for the 2 responders for whom data was available.

Conclusions : Subretinal gene therapy with AGTC-401 resulted in clinically-meaningful and sustained improvement in light discomfort in some participants with CNGB3 ACHM. Fewer individuals showed a response after treatment with AGTC-402 in the CNGA3 trial. Further study is needed to understand the bilateral nature of the LDT improvement.

This abstract was presented at the 2022 ARVO Annual Meeting, held in Denver, CO, May 1-4, 2022, and virtually.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×